BMRN

Prezzo BioMarin Pharmaceutical Inc

BMRN
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-28 23:28 (UTC+8)

As of 2026-04-28 23:28, BioMarin Pharmaceutical Inc (BMRN) is priced at $0, with a total market cap of $10,25B, a P/E ratio of 32,66, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 1,13M. Over the past 52 weeks, BMRN has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

BMRN Key Stats

Yesterday's Close$53
Market Cap$10,25B
Volume1,13M
P/E Ratio32,66
Dividend Yield (TTM)0,00%
Diluted EPS (TTM)1,81
Net Income (FY)$348,90M
Revenue (FY)$3,22B
Earnings Date2026-05-04
EPS Estimate1,00
Revenue Estimate$754,16M
Shares Outstanding190,51M
Beta (1Y)0.291

About BMRN

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
SectorHealthcare
IndustryBiotechnology
CEOAlexander Hardy
HeadquartersSan Rafael,CA,US
Official Websitehttps://www.biomarin.com
Employees (FY)3,22K
Average Revenue (1Y)$1,00M
Net Income per Employee$108,32K

BioMarin Pharmaceutical Inc (BMRN) FAQ

What's the stock price of BioMarin Pharmaceutical Inc (BMRN) today?

x
BioMarin Pharmaceutical Inc (BMRN) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for BioMarin Pharmaceutical Inc (BMRN)?

x

What is the price-to-earnings (P/E) ratio of BioMarin Pharmaceutical Inc (BMRN)? What does it indicate?

x

What is the market cap of BioMarin Pharmaceutical Inc (BMRN)?

x

What is the most recent quarterly earnings per share (EPS) for BioMarin Pharmaceutical Inc (BMRN)?

x

Should you buy or sell BioMarin Pharmaceutical Inc (BMRN) now?

x

What factors can affect the stock price of BioMarin Pharmaceutical Inc (BMRN)?

x

How to buy BioMarin Pharmaceutical Inc (BMRN) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

BioMarin Pharmaceutical Inc (BMRN) Latest News

2026-02-11 08:56

Tom Lee看好MrBeast进军金融,或成新一代Robinhood与“数字银行入口”

财资公司BitMine Immersion(BMRN)董事长Tom Lee在香港共识大会上表示,下一代具有颠覆力的金融平台,可能并非来自华尔街,而是诞生于YouTube生态。Lee认为,全球顶级内容创作者MrBeast进军金融服务领域,或将成为Z世代与Alpha世代的“主流金融入口”,并在未来承担类似Robinhood与嘉信理财的角色。 本月早些时候,MrBeast旗下公司同意收购新银行Step,而BitMine已向该公司投资约2亿美元。Lee指出,这并非一次短期资本运作,而是面向年轻人金融需求变化的长期布局。“Beast有机会成为他们这一代的金融机构,”他说。 Lee将这一趋势与以往世代的金融平台更替作类比:嘉信理财服务于婴儿潮一代,BlackRock和Blackstone吸引X世代资本,而Robinhood赢得了千禧一代。如今,Z世代与Alpha世代正在形成自己的金融消费路径。仅在美国,这两代人规模约1.2亿,而MrBeast在全球拥有超过10亿粉丝,具备天然的用户基础和信任优势。 “这些年轻用户现在或许尚未积累大量财富,但未来十年,他们将经历一次大规模的代际财富转移,”Lee表示。他认为,如果Step成为他们日常使用的金融平台,那么围绕MrBeast构建的金融生态,将自然成为这一代人接触数字资产和新型金融工具的重要渠道。 在Lee看来,年轻群体对数字化资产与线上金融服务的接受度更高,内容平台与金融基础设施的结合,可能重塑未来的金融格局。随着创作者经济与加密金融的融合加速,MrBeast的金融布局,正在被视为通往下一代资本市场的关键通道之一。

Hot Posts su BioMarin Pharmaceutical Inc (BMRN)

K-LinePoet

K-LinePoet

04-11 01:45
2026年3月12日, 拜玛林制药(BMRN)披露1笔公司内部人交易情况。高管Guyer Charles Greg于2026年3月11日卖出1.65万股。 **【近期内部交易】** | 披露日期 | 职位 | 姓名 | 交易日期 | 买/卖 | 数量 | 每股成交价/美元 | 总金额/美元 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2026年3月12日 | 高管 | Guyer Charles Greg | 2026年3月11日 | 卖出 | 1.65万 | 60.46 | 99.67万 | | 2026年2月26日 | 高管 | Friberg Gregory R | 2026年2月26日 | 卖出 | 6326 | 60.38 | 38.19万 | | 2026年2月26日 | 高管 | Davis George Eric | 2026年2月26日 | 卖出 | 2.61万 | 61.36 | 159.91万 | | 2026年2月13日 | 高管 | Guyer Charles Greg | 2025年4月30日 | 买入 | 317 | 54.14 | 1.72万 | | 2026年2月13日 | 高管 | Davis George Eric | 2025年4月30日 | 买入 | 375 | 54.14 | 2.03万 | | 2026年2月13日 | 高管 | Guyer Charles Greg | 2025年10月31日 | 买入 | 62 | 45.54 | 2823.17 | | 2026年2月13日 | 高管 | Mueller Brian | 2025年4月30日 | 买入 | 375 | 54.14 | 2.03万 | | 2026年2月13日 | 高管 | Hubbard Cristin | 2025年10月31日 | 买入 | 80 | 45.54 | 3642.80 | | 2026年2月13日 | 高管 | Friberg Gregory R | 2025年10月31日 | 买入 | 398 | 45.54 | 1.81万 | | 2025年12月2日 | 董事 | Hardy Alexander | 2025年4月30日 | 买入 | 375 | 54.14 | 2.03万 | **【公司资料】** Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立,并于1997年3月21日开始运营。该公司是一家全球性生物技术公司,致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品,这些疾病和病症具有很好的生物学理解,并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。
1
0
0
0